Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 6Venous Thromboembolism 3Venous Thrombosis 2Thrombosis 2Thromboembolism 2Prostatic Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Sarcoma, Alveolar Soft Part 1Pulmonary Embolism 1Prostate Cancer Patients 1Pharmacokinetics of MDV3100 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Hematologic Neoplasms 1Embolism and Thrombosis 1Embolism 1Cytochrome P450 Interaction 1Advanced Solid Tumor 1ALK-positive Advanced Tumors 1

Interventions

Injections 26toripalimab 17pembrolizumab 17tislelizumab 12Gemcitabine 8Cisplatin 7spartalizumab 6atezolizumab 6Irinotecan 6Carboplatin 6Paclitaxel 5Oxaliplatin 5Nivolumab 5Leucovorin 5Fluorouracil 5camrelizumab 4Pemetrexed 4Docetaxel 4Cetuximab 4Capecitabine 4trastuzumab deruxtecan 3sintilimab 3olaparib 3lenvatinib 3cediranib 3PM 01183 3Drug Therapy 3Cyclophosphamide 3Bevacizumab 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Solid Tumor × Warfarin × Clear all
NCT04887194 2024-05-08

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

Mirati Therapeutics Inc.

Phase 1 Completed
40 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡